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BSTRACT
 
Background
 
In infants and children with mater-
nally acquired human immunodeficiency virus type
1 (HIV-1) infection, treatment with a single antiretrovi-
ral agent has limited efficacy. We evaluated the safety
and efficacy of a three-drug regimen in a small group
of maternally infected infants.
 
Methods
 
Zidovudine, didanosine, and nevirapine
were administered in combination orally to eight in-
fants 2 to 16 months of age. The efficacy of antiretro-
viral treatment was evaluated by serial measurements
of plasma HIV-1 RNA, quantitative plasma cultures,
and quantitative cultures of peripheral-blood mono-
nuclear cells.
 
Results
 
The three-drug regimen was well tolerat-
ed, without clinically important adverse events.
Within four weeks, there were reductions in plasma
levels of HIV-1 RNA of at least 96 percent (1.5 log) in
seven of the eight study patients. Over the 6-month
study period, replication of HIV-1 was controlled in
two infants who began therapy at 2
 
1
 
⁄
 
2
 
 months of age.
Plasma RNA levels were reduced by 0.5 to 1.5 log in
five of the other six infants.
 
Conclusions
 
Although further observations are
needed, it appears that in infants with maternally
acquired HIV-1 infection, combined treatment with
zidovudine, didanosine, and nevirapine is well tol-
erated and has sustained efficacy against HIV-1.
(N Engl J Med 1997;336:1343-9.)
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VER the past decade, the numbers of in-
fants infected by the transmission of human
immunodeficiency virus type 1 (HIV-1)
from their mothers have increased great-
ly.
 
1
 
 In general, the depletion of CD4 cells and the
progression of HIV-1–related disease are more rapid
in infants and children than in adults infected with
HIV-1.
 
2
 
 Effective interventional therapies for mater-
nally infected children are needed.
For HIV-1–infected children, therapy has primarily
consisted of a single inhibitor of reverse transcriptase,
and its efficacy has been moderate and limited in du-
ration. Recently, studies in adults
 
3-6
 
 have documented
continuous, high-level replication of HIV-1 even early
in infection. These data have helped explain the limi-
tations of prior therapeutic approaches and suggest
that the best chance of preventing disease after
HIV-1 infection lies in controlling replication of the
virus as early in the course of infection as possible.
O
 
Moderate reductions in the load of HIV-1 in blood
have been documented in infants who received ne-
virapine alone or in combination with zidovudine.
 
7
 
Therefore, we sought to study the antiretroviral ef-
ficacy of a three-drug regimen consisting of zidovu-
dine, didanosine, and nevirapine administered orally
to maternally infected infants and children. Efforts
were made to begin the combined treatment in the
first few months of life.
 
METHODS
 
Study Design
 
This open-label, phase 1–2 study was conducted at two pedi-
atric AIDS Clinical Trials Group (ACTG) sites (the Western New
England Pediatric ACTG Consortium and the University of
California, Los Angeles). HIV-1–infected infants 2 through 24
months of age were eligible for the study, but enrollment focused
on infants under the age of 4 months. The details of the criteria
for inclusion and exclusion, concomitant medications, and the
schedule of evaluations have previously been described.
 
7
 
 Before
enrollment, each participant had a complete history taking and
physical examination, an evaluation of medications, and an electro-
cardiogram; a complete blood count; measurements of electrolytes,
blood urea nitrogen, and creatinine; and tests of liver and thyroid
function.
At each study visit, potential toxic effects of medications or
HIV-1–related symptoms were assessed and a complete physical
examination was performed. Height and weight were measured at
entry into the study and monthly thereafter. The laboratory as-
sessment of potential toxic effects of medications was made at en-
rollment, on days 14 and 28, and monthly thereafter. Studies of
lymphocyte surface markers were performed at enrollment and on
days 28, 56, 84, and 168. Blood to measure the trough plasma
concentration of nevirapine was obtained just before the nevira-
pine dose given at entry and on days 14, 28, 42, 56, 70, 84, and
168. Blood was collected to obtain viral isolates and measure
plasma HIV-1 RNA at enrollment and on days 14, 28, 42, 56,
70, 84, 112, 140, and 168. Medications were dispensed monthly,
and the doses were adjusted for the infant’s growth as necessary.
These studies were approved by the human-subjects commit-
tees at the participating sites; written informed consent was ob-
tained from the patients’ legal guardians. The guidelines of the
U.S. Department of Health and Human Services governing ex-
perimentation in humans were followed.
Copyright © 1997 Massachusetts Medical Society. All rights reserved. 
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Study Medications
 
The following doses of the study drugs were used: 120 mg of
nevirapine (Viramune, Boehringer–Ingelheim) per square meter of
body-surface area, given once daily for 28 days, after which time
200 mg per square meter was given every 12 hours; 180 mg of
zidovudine (Retrovir, Glaxo Wellcome) per square meter, given
every 8 hours; and 120 mg of didanosine (Videx, Bristol-Myers
Squibb) per square meter, given every 12 hours. All the medica-
tions were supplied as suspensions or syrup (nevirapine, 5 and
10 mg per milliliter; zidovudine, 10 mg per milliliter; and didan-
osine, 10 mg per milliliter).
 
Measurement of Plasma Nevirapine
 
Plasma nevirapine concentrations were measured by high-per-
formance liquid chromatography with a validated procedure, as
previously described.
 
7
 
Determination of Lymphocyte Subgroups
 
The relative percentages of CD3
 

 
CD4
 

 
, CD3
 

 
CD8
 

 
,
CD8
 

 
DR
 

 
, CD8
 

 
CD38
 

 
, and CD8
 

 
CD57
 
 
 
lymphocytes in
peripheral blood were determined by direct immunofluorescence
with fluorescein isothiocyanate or phycoerythrin-conjugated mouse
monoclonal antibodies (Becton Dickinson). Samples were ana-
lyzed by flow cytometry (FACScan, Becton Dickinson).
 
Quantitative Cultures of Plasma and Peripheral-Blood 
Mononuclear Cells
 
Quantitative cultures of plasma and peripheral-blood mononu-
clear cells (PBMCs) were performed by limiting-dilution methods
with standard protocols.
 
8
 
Detection and Quantitation of HIV-1 Genomes in PBMCs
 
A commercially available kit (Roche Diagnostic Systems) was
used to detect and quantify the HIV-1 genome in the PBMCs of
the study patients by the polymerase chain reaction (PCR).
 
9
 
Quantitation of Plasma HIV-1 RNA by PCR
 
HIV-1 RNA was quantified in 200 
 
m
 
l of EDTA-anticoagulated
plasma (stored at 
 

 
70°C within six hours after phlebotomy) by
PCR after reverse transcription (Amplicor, Roche). The lower limit
of detection of the assay is 400 copies of HIV-1 RNA per milliliter
of plasma.
 
10
 
 All the assays were performed in a laboratory that par-
ticipates in an ongoing certification program for HIV RNA quan-
titation sponsored by the National Institutes of Health.
 
10
 
 The base-
line plasma level of HIV-1 RNA was defined as the arithmetic
mean of two measurements obtained within one month of the start
of therapy. Sequential plasma samples from individual patients were
assayed in batches to avoid variability between assays.
In two children, the HIV-1 RNA values measured after treat-
ment began were below the detection limit of the standard assay.
Plasma samples from these children were subsequently tested
with 450 
 
m
 
l of plasma and a modified assay that had a detection
limit of 20 copies of HIV-1 RNA per milliliter.
 
11
 
HIV-1–Specific Immune Responses
 
Plasma HIV-1 IgG antibodies were measured with a commer-
cial immunoassay (Cambridge Biotech). The specificity of plasma
IgG antibodies for the HIV-1 gene product was assessed by a
Western blot assay (Cambridge Biotech). A dot blot assay was used
to detect plasma IgA antibodies.
 
12
 
 Assays to detect HIV-1–specific
cytotoxic T lymphocytes were performed after virus-specific stimu-
lation of PBMCs.
 
13
 
Measurement of Antibodies to Childhood Vaccines
 
Routine childhood immunizations were administered accord-
ing to the recommended schedule. IgG antibodies to 
 
Haemoph-
ilus influenzae
 
 and hepatitis B surface antigen were measured by
an enzyme-linked immunosorbent assay (ELISA).
 
RESULTS
 
Study Patients
 
Eight maternally infected children 2 to 16 months
of age (three female and five male) were enrolled in
this study; six were 4 months old or less at enroll-
ment (Table 1). All the patients were asymptomatic
or only mildly symptomatic
 
15
 
 at study entry. Three
children (Patients 5, 6, and 8) had never received an-
tiretroviral therapy. The remaining five had received
zidovudine therapy.
The regimen of antiretroviral drugs used was well
tolerated by all the study patients. No clinically sig-
nificant adverse events related to the study drugs
were reported.
 
Plasma Nevirapine Concentrations
 
The patients’ median trough plasma concentra-
tions of nevirapine during the treatment period
ranged from 2.7 to 8.6 
 
m
 
g per milliliter. There was
no apparent association between the trough concen-
tration of nevirapine in plasma and the reduction in
plasma HIV-1 RNA (data not shown).
 
Effect of Treatment on the HIV-1 Load 
in Peripheral Blood
 
The patients’ plasma HIV-1 RNA levels before
therapy ranged from approximately 41,000 to approx-
imately 1.5 million copies per milliliter (Fig. 1). All the
patients had rapid reductions in plasma HIV-1 RNA;
 
*Patients 2 and 3 were fraternal twins.
†The definitions of the timing of infection were those used by Bryson
et al.
 
14
 
‡Clinical stages were those in the definitions of the Centers for Disease
Control and Prevention.
 
15 
 
A denotes asymptomatic, 1 normal CD4 counts
for age, and 2 mildly reduced CD4 counts for age.
§Data are for CD4 cells as a proportion of all lymphocytes.
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CD4
(%)§
HIV-1 RNA
(
 
COPIES
 
/
 
ml
 
)
 
1 2 Unknown A1 Zidovudine for 
6 wk
38 1,546,242
2 2
 
1
 
⁄
 
2
 
Late A1 Zidovudine for 
5 wk
58 295,022
3 2
 
1
 
⁄
 
2
 
Late A1 Zidovudine for 
5 wk
44 331,036
4 2
 
1
 
⁄
 
2
 
Early A1 Zidovudine for 
10 wk
56 244,374
5 3 Unknown A1 None 31 466,590
6 4 Unknown A1 None 32 41,516
7 12 Unknown A1 Zidovudine for 
16 wk
28 572,424
8 16 Unknown A2 None 18 195,994
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Figure 1.
 
 Effect of Combination Therapy with Zidovudine, Didanosine, and Nevirapine on Plasma Levels of HIV-1 RNA ( ) and
on CD4 T Lymphocytes ( ) in Peripheral Blood as a Percentage of All Lymphocytes.- - - - - - -
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minimal reductions of 96 percent (a decrease of 1.5
in the log of the number of copies per milliliter)
were observed in seven of the eight infants within
two to four weeks of the start of therapy. Plasma
HIV-1 RNA levels remained below the base-line lev-
els (falling to 4 to 30 percent of base line) through
the entire six months of therapy in seven of the eight
infants.
Plasma HIV-1 RNA levels remained below the
base-line levels throughout the six months of thera-
py in five of the six infants whose treatment began
at four months of age or less. Three of these six in-
fants had lasting reductions of at least 96 percent
(1.5 log) in their plasma RNA levels over the six
months of the study, including a pair of fraternal
twins (Patients 2 and 3) in whom these levels fell be-
low 400 copies per milliliter by days 168 and 56, re-
spectively.
The base-line plasma HIV-1 cultures were positive
in five of the eight infants at titers ranging from 62
to 7812 tissue-culture infectious doses per milliliter
(Table 2). All five of these infants were three months
old or less, and only one (Patient 4) was receiving
zidovudine when the culture was obtained. Infec-
tious HIV-1 was undetectable in plasma in all the in-
fants by day 28 of therapy and remained undetect-
able through day 168 in six. One infant (Patient 1)
had a positive plasma culture at day 168 and had
negative cultures on subsequent follow-up. Plasma
cultures from Patient 4 were negative on days 28 and
84; not enough blood was obtained from this pa-
tient for plasma cultures to be performed at the end
of the study.
HIV-1 was isolated from PBMCs from all infants
at least twice before therapy began; HIV-1 titers in
the PBMC cultures before therapy ranged from 8 to
206 infectious units per million cells (Table 3). Re-
ductions in these titers were noted in all the infants
but one by day 28, and all the infants had reduced
titers on day 168. PBMC cultures became negative
in Patients 2, 3, and 4.
Throughout the study period, HIV-1 provirus
was detected by PCR in PBMCs from all the infants,
including Patients 2 and 3.
 
Effects of Treatment on Lymphocytes
 
At entry into the study, the percentage of CD4
T lymphocytes in the peripheral blood was normal
for the patient’s age in all but one infant (Patient
8). The percentage of CD4 T lymphocytes in the
peripheral blood remained stable or increased slight-
ly in all the patients over the course of the study
(Fig. 1).
Hypergammaglobulinemia has been frequently
described in infants with HIV-1 infection and is
thought to be due to the activation of B cells by the
virus. When they were tested at about the age of one
year, three of five infants who began the three-drug
regimen before the age of four months had hyper-
gammaglobulinemia (data not shown). In Patients
2 and 3, the total plasma IgG levels measured at 13
and 16 months were within the normal limits for the
patient’s age.
Numbers of CD8 T lymphocytes are expanded
early in infants infected by their mothers, largely
because of an expansion in the CD8
 

 
CD57
 
 
 
and
CD8
 

 
DR
 

 
 populations.
 
16
 
 In this study, expand-
ed populations of CD8
 

 
CD57
 

 
 and CD8DR
T lymphocytes were found in the peripheral blood
of infants who had persistently detectable plasma
HIV-1 RNA during treatment (data not shown).
These lymphocyte populations were not expanded
in Patients 2 and 3.
TABLE 2. CHANGES IN HIV-1 TITERS IN 
PLASMA CULTURES OVER TIME.
PATIENT 
NO.
AGE AT
ENTRY 
(MO) PLASMA HIV-1 TITER
BASE 
LINE
DAY 
28
DAY 
168
tissue-culture infectious doses/ml
1 2 7812 0 62
2 21⁄2 312 0 0
3 21⁄2 62 0 0
4 21⁄2 62 0 Not done
5 3 312 0 0
6 4 0 0 0
7 12 0 0 0
8 16 0 0 0
TABLE 3. CHANGES IN HIV-1 TITERS IN
PBMCS OVER TIME.
PATIENT 
NO.
AGE AT
ENTRY 
(MO) PBMC HIV-1 TITER
BASE 
LINE
DAY
28
DAY 
168
infectious units/ 
million cells
1 2 206 16 2
2 21⁄2 82 8 0
3 21⁄2 16 1 0
4 21⁄2 28 9 0
5 3 206 16 16
6 4 43 82 0.5
7 12 143 3 0.5
8 16 8 0 3
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Immune Responses to HIV-1 and Childhood 
Immunizations
Diminished antibody responses to routine child-
hood immunizations have been described in chil-
dren with HIV-1 infection.17 The plasma HIV-1 IgG
titers measured by ELISA in Patients 2 and 3 de-
creased with time and became negative (Fig. 2); the
kinetics of the HIV-1–antibody clearance was iden-
tical to that observed in uninfected infants born
to HIV-1–seropositive mothers. Concomitantly, the
loss of plasma IgG antibodies to HIV-1 gene prod-
ucts was noted on the Western blot assay (data not
shown). HIV-1–specific IgA antibodies were not
found in the plasma of either Patient 2 or Patient 3
at 6 and 12 months of age. In contrast, infants who
remained positive for plasma HIV-1 RNA produced
HIV-1–specific IgG antibodies actively. Altogether,
the data suggest that the IgG antibodies detected
early in Patients 2 and 3 were passively acquired ma-
ternal antibodies that were cleared with time. The
failure to produce HIV-1–specific antibodies is con-
sistent with the marked suppression of HIV-1 repli-
cation in these two infants.
Antibody responses to H. influenzae and hepatitis
B virus antigens given at immunization were detect-
ed in the peripheral blood of Patients 2 and 3 (data
not shown). Variable antibody responses to vaccine
antigens were noted in all the other infants.
There was sufficient in vitro proliferation of PBMCs
to permit testing for HIV-1–specific cytotoxic T lym-
phocytes only in samples obtained at 31⁄2 months of
age from Patient 2 and only in samples obtained at
31⁄2 and 10 months of age from Patient 3, despite
good in vitro proliferation of PBMCs at the same
times in response to monoclonal antibody to CD3.
No responses of HIV-1–specific cytotoxic T lym-
phocytes were detected in PBMCs from Patients
2 and 3.
Follow-up of the Two Infants with Undetectable Plasma 
HIV-1 RNA
Longer follow-up of Patients 2 and 3 was under-
taken. Since HIV-1 RNA was repeatedly undetect-
able in their plasma by the routine assay, plasma
samples from these infants were also studied by an
ultrasensitive assay with a detection limit of 20 cop-
ies per milliliter.11 In Patient 2, plasma HIV-1 RNA
levels remained below 20 copies per milliliter through
month 15 of therapy. At 16 months, plasma HIV-1
RNA was detected on two occasions 2 weeks apart
(1117 and 1546 copies per milliliter). A review of
the records for Patient 2 showed that the child had
received an influenza immunization 12 days before
HIV-1 RNA was first detected. Therapy with zi-
dovudine, didanosine, and nevirapine was discon-
tinued, and a regimen consisting of zidovudine,
lamivudine (Epivir, Glaxo Wellcome), and ritonavir
(Norvir, Abbott Laboratories) was instituted. Three
weeks after the antiretroviral therapy was switched,
the plasma HIV-1 RNA level was again below 400
copies per milliliter, and it remained at that level
throughout an additional month of follow-up (month
18). Interestingly, HIV-1–specific IgG antibodies
were detected by ELISA and the Western blot assay
in this child’s plasma concurrently with the detec-
tion of HIV-1 RNA. Despite the transient detection
of plasma HIV-1 RNA, HIV-1 has not been recov-
ered from plasma or PBMCs. Peripheral-blood CD4
and CD8 T-cell counts have remained normal for
the patient’s age.
Patient 3 has continued to be treated with zido-
vudine, didanosine, and nevirapine for 18 months.
During this period, she has received all routine
childhood immunizations. Her plasma HIV-1 RNA
level has remained below 20 copies per milliliter. No
HIV-1–specific IgG antibodies have been detectable
in plasma by ELISA. The HIV-1 genome has been
persistently detected at a level of 100 to 178 copies
per million CD4 T lymphocytes. The proportions of
CD4 and CD8 T lymphocytes have remained nor-
mal for the patient’s age.
DISCUSSION
We evaluated the safety and antiretroviral activity
of a three-drug combination therapy in HIV-1–
infected infants and children. Since six of the eight
Figure 2. Changes in Plasma Titers of HIV-1 Antibody over Time
in Four HIV-1–Infected Patients Given Three-Drug Combination
Therapy and Two Uninfected Infants Born to HIV-1–Infected
Mothers.
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infants began their therapy before the age of five
months, we also evaluated the efficacy of the combi-
nation therapy when it was begun early in the course
of maternally acquired HIV-1 infection. The treat-
ment was well tolerated, with no clinically significant
adverse events. Of the eight infants, seven had reduc-
tions of at least 0.5 log in their plasma HIV-1 RNA
levels throughout the six months of therapy. The an-
tiretroviral activity of the combination therapy in
maternally infected infants was therefore similar to
that reported in adults with no previous antiretrovi-
ral therapy.18
In a study of nevirapine monotherapy,7 the loss of
antiretroviral activity over time was associated with
the isolation of viruses with decreased in vitro sen-
sitivity to nevirapine. In our study, all the viruses
isolated from the study patients before therapy
were sensitive to nevirapine (data not shown). Virus-
es with decreased sensitivity to nevirapine were iso-
lated during the treatment period from all five in-
fants (Patients 1, 4, 5, 6, and 8) who had partial
rebounds in their plasma HIV-1 RNA levels. Viruses
isolated from Patients 2, 3, and 7 remained suscep-
tible to nevirapine. The emergence of resistance may
explain the partial loss of antiretroviral activity ob-
served in some infants.
Over the six months of the study, there was clear-
ance of detectable plasma HIV-1 RNA in a pair
of fraternal twins (Patients 2 and 3) who had the
intrapartum (or “late”) pattern of infection. The
twins began combination therapy at the age of 21⁄2
months. Their outcomes after three-drug therapy
have differed during follow-up. Although the base-
line plasma HIV-1 RNA levels in Patients 2 and 3
were similar, HIV-1 RNA was cleared more rapidly
from the plasma of Patient 3 and remained unde-
tectable through month 18 of therapy. Patient 2 was
slower to have clearance of HIV-1 RNA, and RNA
was detected again in this infant’s plasma after month
16 of therapy. 
Interestingly, infectious plasma and PBMC titers
before therapy were higher in Patient 2 than in Pa-
tient 3, suggesting that Patient 2 may have had a
higher initial inoculum of infectious virus. Although
these twins were probably infected with a single viral
strain or with closely related strains, infection with
different strains could explain the divergent out-
comes. However, host factors, such as the size of the
pool of activated CD4 T lymphocytes and differ-
ences in immune responses, may have influenced
the outcomes. Extinguishing HIV-1 replication took
longer in both infants than the estimated two to
three weeks previously proposed.6 This may be due
to differences in the potency or mechanisms of ac-
tion of the antiretroviral drugs used. Alternatively,
the slower rate of HIV-1 RNA clearance may be due
to the larger pools of activated CD4 T lymphocytes
in young infants.
It has been predicted that during primary infec-
tion in adults, using therapeutic regimens that com-
pletely inhibit viral replication may lead to the com-
plete eradication of HIV-1 within two to three years.
Whether continued control of HIV-1 replication
and eventual viral eradication will occur in Patients
2 and 3 with the current combination of drugs de-
pends on the longevity of the infected cell popula-
tions, the proportion of latently infected cells that is
capable of producing infectious viruses, and the ul-
timate efficiency of the combination therapy in pre-
venting new infections of cells. It may also depend
on the ability of antiretroviral agents to penetrate
potential “sanctuary” sites, such as the central nerv-
ous system, and control viral replication there. Both
zidovudine and nevirapine penetrate the central
nervous system well. 
We studied HIV-1–specific and general immune
responses in the infants who began three-drug ther-
apy before the age of four months. Active pro-
duction of HIV-1–specific antibodies was docu-
mented in all the children with ongoing replication
of HIV-1. In contrast, the active production of
HIV-1 IgA and IgG antibodies was not observed in
Patients 2 and 3, even though high titers of in-
fectious virus were isolated from their plasma and
PBMCs for several weeks before therapy. This find-
ing is compatible with one of documented sero-
reversion in an infant recently reported to have had
clearance of maternally acquired HIV-1 infection19
and with the transient, low-level antibody produc-
tion in neonatal macaques with limited replication
of simian immunodeficiency virus in early infec-
tion.20 The presence of high titers of maternal HIV-1
antibody when viral replication began may have
dampened primary humoral immune responses. Al-
ternatively, the large number of CD4 T cells initially
infected may have impaired helper function and may
account for the lack of detectable HIV-1–specific
humoral and cytotoxic-T-lymphocyte responses. The
normal immunoglobulin levels for the patient’s age,
the responses to vaccine antigens, and the subse-
quent seroconversion in Patient 2 suggest that in-
fants who begin combination antiretroviral therapy
early are capable of normal humoral immune re-
sponses.
Although most of the study patients were treated
earlier and more aggressively than is currently the
standard of care, our data suggest that instituting po-
tent antiretroviral therapies even earlier is desirable.
The high base-line plasma HIV-1 RNA levels and the
rapid, profound reductions we observed in these lev-
els are consistent with extremely rapid rates of viral
turnover. Coffin21 has estimated that, on average, a
mutation occurs several times daily at every position
in the HIV-1 genome. Although minimal genotypic
heterogeneity has been described in even highly vari-
able regions (such as the V3 region of the envelope
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protein22,23) of isolates obtained in early maternally
acquired infection, our data suggest that by the age
of two to three months diversification may have oc-
curred to such a degree that mutations conferring re-
sistance to antiretroviral drugs were present before
therapy and were selected during therapy.
Altogether, these considerations suggest that ther-
apy with potent combinations of antiretroviral drugs
should be started as early as possible in infants with
maternally acquired infection (probably within the
first two to four weeks), to minimize the likelihood
that antiretroviral resistance will emerge and to max-
imize the opportunity for long-term control of HIV-1
replication. Recent advances in the ability to diag-
nose maternally acquired HIV-1 infection within
weeks of infection24 should permit this strategy to be
evaluated.
Supported in part by the AIDS Clinical Trial Group (AIDS Clinical Trials
Group protocol 180) and the National Institute of Allergy and Infectious
Diseases, National Institutes of Health (AI32907, AI27550, and AI30629);
by the General Clinical Research Center Units, National Center for Re-
search Resources (University of Connecticut and University of California at
Los Angeles); and by Boehringer–Ingelheim Pharmaceuticals. Dr. Luzuria-
ga is an Elizabeth Glaser Scientist of the Pediatric AIDS Foundation.
We are indebted to the study patients and their guardians for
their participation; to Heather Macy, Maureen Myers, and Eliza-
beth Hawkins for their help with protocol development and study
management; to Joe Pav for the analysis of plasma nevirapine levels;
to Jerry Durbin, Donna Picard, Amy Sharples, Dottie Smith, Lor-
raine Wells, Maripat Toye, and Dena Jung for clinical assistance;
to Kevin Byron, Balaka Roy, Linda Lambrecht, Richard Hudson,
Michelle Sicard, Frank Brewster, and Ruth Dickover for the virologic
assays; to John Mulder (Roche Molecular Systems, Inc.) for the ultra-
sensitive RNA assays; to Carmen White and Diane Wara for the
HIV-1–specific IgA assays; to Margaret McManus for graphics and
data management; and to Melinda Gromack for assistance in the
preparation of the manuscript.
REFERENCES
1. Stoneburner RL, Sato P, Burton A, Mertens T. The global HIV pan-
demic. Acta Paediatr Suppl 1994;400:1-4.
2. The European Collaborative Study. Natural history of vertically ac-
quired human immunodeficiency virus-1 infection. Pediatrics 1994;94:
815-9.
3. Piatak M Jr, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma 
during all stages of infection determined by competitive PCR. Science 
1993;259:1749-54.
4. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz 
M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 in-
fection. Nature 1995;373:123-6.
5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immuno-
deficiency virus type 1 infection. Nature 1995;373:117-22.
6. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and 
viral generation time. Science 1996;271:1582-6.
7. Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety, and 
activity of nevirapine in human immunodeficiency virus type 1-infected 
children. J Infect Dis 1996;174:713-21.
8. AIDS Clinical Trials Group. Virology reference manual. Bethesda, Md.:
National Institutes of Health, 1993.
9. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan 
JL. HIV-1–specific cytotoxic T lymphocytes (CTL), viral load, and CD4 
T cell loss: evidence supporting a predominantly protective role for CTL 
in vivo. J Infect Dis (in press).
10. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in 
clinical practice. Nat Med 1996;2:625-9.
11. Christopherson C, Mulder J, Conway B, et al. Evaluation of HIV-1 
proviral DNA in patients with undetectable RNA. Presented at the Fourth 
Conference on Retroviruses and Opportunistic Infections, Washington, 
D.C., January 22–26, 1997.
12. Martin NL, Levy JA, Legg H, Weintrub PS, Cowan MJ, Wara DW. 
Detection of infection with human immunodeficiency virus (HIV) type 1 
in infants by an anti-HIV immunoglobulin A assay using recombinant pro-
teins. J Pediatr 1991;118:354-8.
13. Lubaki MN, Egan MA, Siliciano RF, Weinhold KJ, Bollinger RC. A 
novel method for detection and ex vivo expansion of HIV type 1-specific 
cytolytic T lymphocytes. AIDS Res Hum Retroviruses 1994;10:1427-31.
14. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions 
for in utero versus intrapartum transmission of HIV-1. N Engl J Med 
1992;327:1246-7.
15. 1994 Revised classification system for human immunodeficiency virus 
infection in children less than 13 years of age. MMWR Morb Mortal Wkly 
Rep 1994;43(RR-12):1-10.
16. Luzuriaga K, Koup RA, Pikora CA, Brettler DB, Sullivan JL. Deficient 
human immunodeficiency virus type 1-specific cytotoxic T cell responses 
in vertically infected children. J Pediatr 1991;119:230-6.
17. Peters VB, Sood SK. Immunity to Haemophilus influenzae type b pol-
ysaccharide capsule after vaccination with the complete series of oligosac-
charide CRM197 conjugate vaccine in infants with human immunodeficien-
cy virus infection. J Pediatr 1996;128:363-5.
18. Myers M, Montaner J, Group IS. A randomized, double-blinded com-
parative trial of the effects of zidovudine, didanosine, and nevirapine com-
binations in antiviral naive, AIDS-free, HIV-infected patients with CD4 
counts 200–600/mm3. In: Abstracts of the XI International Conference 
on AIDS, Vancouver, B.C., July 7–12, 1996:22. abstract.
19. Bryson YJ, Pang S, Wei LS, Dickover R, Diagne A, Chen ISY. Clear-
ance of HIV infection in a perinatally infected infant. N Engl J Med 1995;
332:833-8.
20. Wyand MS, Manson KH, Lackner AA, Desrosiers RC. Resistance of 
neonatal monkeys to live attenuated vaccine strains of simian immunodefi-
ciency virus. Nat Med 1997;3:32-6.
21. Coffin JM. HIV population dynamics in vivo: implications for genetic 
variation, pathogenesis, and therapy. Science 1995;267:483-9.
22. Scarlatti G, Leitner T, Halapi E, et al. Comparison of variable region 
3 sequences of human immunodeficiency virus type 1 from infected chil-
dren with the RNA and DNA sequences of the virus populations of their 
mothers. Proc Natl Acad Sci U S A 1993;90:1721-5.
23. Wolinsky SM, Wike CM, Korber BTM, et al. Selective transmission of 
human immunodeficiency virus type-1 variants from mothers to infants. 
Science 1992;255:1134-7.
24. Luzuriaga K, Sullivan JL. DNA polymerase chain reaction for the di-
agnosis of vertical HIV infection. JAMA 1996;275:1360-1.
Copyright © 1997 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY MASS MEDICAL SCHOOL on January 7, 2009 . 
